Comparative Effectiveness of Targeted Prostate Biopsy Using MRI-US Fusion Software and Visual Targeting: a Prospective Study.

PURPOSE - To compare diagnostic outcomes between 2 different techniques for targeting regions-of-interest on prostate multiparametric Magnetic resonance imaging (mpMRI); MRI-ultrasound fusion (MR-F) and visually targeted (VT) biopsy.

MATERIALS AND METHODS - Patients presenting for prostate biopsy with regions-of-interest on mpMRI underwent MRI-targeted biopsy. For each region-of-interest two VT cores were obtained, followed by 2 cores using an MR-F device. Our primary endpoint was the difference in the detection of high-grade (Gleason ≥7) and any-grade cancer between VT and MR-F, investigated using McNemar's method. Secondary endpoints were the difference in detection rate by biopsy location using a logistic regression model, and difference in median cancer length using Wilcoxon sign-rank test.

RESULTS - We identified 396 regions-of-interest in 286 men. The difference in high-grade cancer detection between MR-F biopsy and VT biopsy was -1.4% (95% CI -6.4% to 3.6%; p=0.6); for any-grade cancer the difference was 3.5% (95% CI -1.9% to 8.9%; p=0.2). Median cancer length detected by MR-F and VT were 5.5mm vs. 5.8mm, respectively (p=0.8). MR-F biopsy detected 15% more cancers in the transition zone (p=0.046), and VT biopsy detected 11% more high-grade cancer at the prostate base (p=0.005). Only 52% of all high-grade cancers were detected by both techniques.

CONCLUSIONS - We found no evidence of a significant difference in the detection of high-grade or any-grade cancer between VT and MR-F biopsy. However, the performance of each technique varied in specific biopsy locations, and the outcomes of both techniques were complementary. Combining VT biopsy and MR-F biopsy may optimize prostate cancer detection.

The Journal of urology. 2016 Mar 30 [Epub ahead of print]

Daniel J Lee, Pedro Recabal, Daniel D Sjoberg, Alan Thong, Justin K Lee, James A Eastham, Peter T Scardino, Hebert Alberto Vargas, Jonathan Coleman, Behfar Ehdaie

Department of Urology, Weill-Cornell Medical College, New York Presbyterian Hospital., Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center; Urology Service, Fundacion Arturo Lopez Perez., Health Outcomes Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center., Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Department of Radiology, Memorial Sloan Kettering Cancer Center., Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center., Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center; Health Outcomes Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center.